N/A
N=4,190
Social and Monetary Incentives for Smoking Cessation at Large Employers
Tobacco Use Disorder
Bottom Line
View on ClinicalTrials.gov: NCT02421224 ↗Enrolled (actual)
4,190
Serious AEs
0.0%
Results posted
Nov 2020
Primary outcome: Primary: Proportion of Participants With Smoking Abstinence at 12 Months — 42; 57; 74; 104 Participants
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Usual Care (Behavioral); Deposits (Behavioral); Small Individual Bonus (Behavioral); Large Individual Bonus (Behavioral); Teammate (Behavioral); Team Bonus (Behavioral)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- University of California, Berkeley
- Primary completion
- Aug 2017
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Proportion of Participants With Smoking Abstinence at 12 Months |
42; 57; 74; 104; 60; 72 | — |
| SECONDARY Proportion of Participants With Smoking Abstinence at 3 Months |
40; 61; 64; 88; 56; 66 | — |
| SECONDARY Program Acceptance |
271; 202; 345; 290; 293; 270 | — |
| SECONDARY Proportion of Participants With Smoking Abstinence at 6 Months |
48; 54; 62; 104; 52; 67 | — |
Summary
The investigators will conduct a cluster randomized controlled trial of several behavioral interventions for smoking cessation among a sample of employees at large workplaces in the Bangkok metropolitan area. The study aims to test the impacts of different incentive structures for smoking cessation on take-up, effectiveness, and cost-effectiveness. The interventions are designed to elucidate certain principles from the field of behavioral economics.
Eligibility Criteria
Inclusion Criteria
- Current full-time employee of a participating company
- Smoker of 100+ cigarettes during lifetime
- Smoker of 10+ cigarettes per week
- Individual is aged 18+ years old
- Smoker wants to quit within the next 6 months
Exclusion Criteria
- Expects to leave company within the next 12 months
- Is currently pregnant
- Are unable to provide informed consent
Data sourced from ClinicalTrials.gov (NCT02421224). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.